TRIM21 and rheumatoid arthritis: Recent studies indicate that RA patients positive for anti-Ro/SSA antibodies represent a distinct clinical subset with higher disease activity, more frequent extra-articular features (such as sicca symptoms), and reduced responsiveness to certain DMARDs (21).